Your best medicine news resource
May 15th 2008Drug InformationBlood
Emotions ran high in Washington yesterday, Tuesday 29th April, as a congressional panel listened to tearful and angry testimonies from family members of how their loved ones died after being given contaminated heparin. Manufacturers and industry regulators also told their story, but panel members were very unhappy with their failure to stop the unsafe blood thinner from entering the US from China.
More: continued here
May 15th 2008Drug InformationBlood
Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dipyridamole Tablets USP, 25mg, 50mg, and 75mg, the generic equivalent of Persantine® Tablets manufactured by Boehringer Ingelheim GmbH. According to Wolters Kluwer, total sales of generic Dipyridamole Tablets were $46 million a year in 2007 at average wholesale price (AWP).
More: continued here
May 15th 2008Drug InformationBlood
Long-term exposure to air pollution appears to be associated with an increased risk of deep vein thrombosis, blood clots in the thigh or legs, according to a report in the May 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
More: continued here
May 15th 2008Drug InformationBlood
Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. CB 813 was created using Catalyst’s proprietary therapeutic protease platform technologies and know-how.
More: continued here
May 15th 2008Drug InformationBlood
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. launch of the TigerWire(TM) Steerable Guidewire. The newest member of the St. Jude Medical GuideRight(TM) family of steerable guidewires, the TigerWire Steerable Guidewire is designed to enhance physicians’ ability to steer through challenging peripheral arteries, the vessels that supply blood to the legs and arms.
More: continued here
May 15th 2008Drug InformationBlood
A new treatment option - Ferriprox Oral Solution - is now available to patients suffering from thalassaemia major, a rare genetic disease with only 50 percent of the patients surviving the age of 35 years1. Thalassaemia patients require blood transfusions to survive, which leads to damaging iron accumulation in the tissues, especially the heart. Ferriprox (deferiprone) is an iron chelator that effectively removes the excess iron from the body caused by blood transfusions.
More: continued here
May 15th 2008Drug InformationBlood
The American Society of Hematology (ASH) is proud to announce the selection of 15 participants for its 2008 Minority Medical Student Award Program (MMSAP), which encourages minority medical students to purse an interest in hematology research. Under the program, each award recipient will receive the support of a research mentor and a career development mentor, travel stipends to attend medical meetings, and a subscription to the scientific journal Blood, the official journal of ASH.
More: continued here
May 15th 2008Drug InformationBlood
Intravenous administration of isotonic fluids is the standard emergency treatment in the U.S. for patients with severe blood loss, but UC San Diego bioengineering researchers have reported improved resuscitation with a radically different approach. Building on earlier studies in humans that have shown benefits of intravenous fluids that are eight times saltier than normal saline, the researchers combined hypertonic saline with viscosity enhancers that thicken blood.
More: continued here
May 15th 2008Drug InformationBlood
The American Society of Hematology (ASH) is proud to announce the 2008 recipients of its Trainee Research Awards. This year 40 medical students, undergraduates, and residents will each receive $4,000 to conduct research on blood and blood-related diseases through this program, which is designed to encourage the pursuit of research and spark an interest in hematology.
More: continued here
May 15th 2008Drug InformationBlood
Medical College of Wisconsin researchers in Milwaukee have shown for the first time that thrombopoietin (TPO), a naturally occurring protein being developed as a pharmaceutical to increase platelet count in cancer patients during chemotherapy, can also protect the heart against injury during a heart attack.The study, led by John E.
More: continued here
Your best medicine news resource
